<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03424265</url>
  </required_header>
  <id_info>
    <org_study_id>206313</org_study_id>
    <nct_id>NCT03424265</nct_id>
  </id_info>
  <brief_title>Nutritional Therapy Interventions in Heart Failure</brief_title>
  <official_title>Effects of 12 Weeks of Nutritional Therapy Interventions in Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will examine the effects of 12-weeks of nutritional interventions in older&#xD;
      participants who have a symptom of mild to moderate heart failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure develops when cardiac muscle becomes weakened and consequently is compromised&#xD;
      in its ability to contract, relax, or both. Impaired heart function leads to reduced exercise&#xD;
      capacity, which in turn leads to progressive muscle weakness and a vicious cycle of sedentary&#xD;
      behavior, weight gain, and subsequent development of metabolic abnormalities and sarcopenia.&#xD;
      Approximately 6-10% of individuals over the age of 65 suffer from heart failure, and the risk&#xD;
      of death is 35% in the first year after diagnosis. In addition, there is a wide range of&#xD;
      potential causes of heart failure, including the natural process of aging. Regardless of the&#xD;
      specific underlying cause, there are common pathophysiological responses such as impaired&#xD;
      exercise capacity, shortness of breath, fatigue and muscle strength, leading to decreased&#xD;
      physical function. Moreover, some long-term consequences of reduced exercise tolerance and&#xD;
      malabsorption in long-standing heart failure are loss of muscle mass and the development of&#xD;
      cardiac cachexia, resulted in progression of sarcopenia. As protein and amino acid&#xD;
      supplements are known to prevent loss of muscle mass or maintain muscle mass in alder&#xD;
      individuals, in a pilot study 18 overweight/obese subjects with heart failure (all exceeded&#xD;
      40% body fat) were studied. Nine subjects received 12 weeks of dietary supplementation with&#xD;
      20 g of whey protein consumed daily, while the other nine were controls. The findings showed&#xD;
      that supplementation with whey protein failed to improve functional performance as well as a&#xD;
      limited stimulation of muscle protein synthesis. The lack of a demonstrable effect of whey&#xD;
      protein is consistent with the diminished responsiveness to the stimulation of muscle protein&#xD;
      synthesis. In contrast, a 2016 University of Arkansas for Medical Sciences (UAMS) pilot study&#xD;
      found that the essential amino acid (EAA) mixture is better at overcoming anabolic resistance&#xD;
      than Ensure Heart Health. In this study we will perform a randomized clinical trial of a&#xD;
      commercially produced nutritional supplement as compared to a placebo in order to determine&#xD;
      effects on physical function and health-related quality of life. Subjects will ingest either&#xD;
      the EAA mixture product or placebo every day for 12 consecutive weeks. Outcomes will be&#xD;
      determined by comparing the results of physical and functional tests from weeks -1 to 6 and&#xD;
      12.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2018</start_date>
  <completion_date type="Actual">June 27, 2019</completion_date>
  <primary_completion_date type="Actual">June 27, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional Test</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <description>Measuring 6 minutes walking before and after the intervention. ***The results below are the actual increases of walking distance (mean and SD) changes from baseline to end of 12-week intervention.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Heart Failure NYHA Class II</condition>
  <arm_group>
    <arm_group_label>9g of EAA mixture supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice a day for 12 consecutive weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9g of placebo (whey protein)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice a day for 12 consecutive weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>EAA mixture</intervention_name>
    <description>Dietary supplement intervention for 12-weeks</description>
    <arm_group_label>9g of EAA mixture supplement</arm_group_label>
    <other_name>Essential Blends, Fairbanks, Alaska</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo (whey protein)</intervention_name>
    <description>Dietary supplement intervention for 12-weeks</description>
    <arm_group_label>9g of placebo (whey protein)</arm_group_label>
    <other_name>Pure Protein, 100% Whey Protein Powder, Bayport, NY</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI between 18 and 40 kg/m2&#xD;
&#xD;
          -  Any ethnicity&#xD;
&#xD;
          -  Presence of mild-to-moderate heart failure (NYHA II or III symptomatology) as&#xD;
             evidenced by prescribed diuretics or reported shortness of breath upon exertion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergic to milk or soy products&#xD;
&#xD;
          -  Hemoglobin &lt;10 g/dL&#xD;
&#xD;
          -  Estimated Glomerular Filtration Rate (eGFR) &lt; 30&#xD;
&#xD;
          -  Inability to perform strength and/or functional assessments&#xD;
&#xD;
          -  Myocardial infarction in the past 6 months&#xD;
&#xD;
          -  Unstable angina&#xD;
&#xD;
          -  Moderate-severe heart valve disease&#xD;
&#xD;
          -  Atrial fibrillation or other significant (as determined by PI) arrhythmias&#xD;
&#xD;
          -  Infiltrative, restrictive or hypertrophic cardiomyopathy&#xD;
&#xD;
          -  Dementia -determined by a SLUMS score of &lt;20&#xD;
&#xD;
          -  Currently having inflammatory bowel disease&#xD;
&#xD;
          -  Received chemotherapy or radiation therapy within the past 12 months&#xD;
&#xD;
          -  Currently undergoing tube feeding&#xD;
&#xD;
          -  Currently receiving palliative care for end-of-life circumstance&#xD;
&#xD;
          -  Unwilling to refrain from using non-study protein/amino acid supplements during their&#xD;
             participation in this study&#xD;
&#xD;
          -  If deemed medically unstable by the study physician for any other reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gohar Azhar, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 31, 2018</study_first_submitted>
  <study_first_submitted_qc>January 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2018</study_first_posted>
  <results_first_submitted>July 8, 2020</results_first_submitted>
  <results_first_submitted_qc>August 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 19, 2020</results_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT03424265/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>9g of EAA Mixture Supplement</title>
          <description>Twice a day for 12 consecutive weeks.&#xD;
EAA mixture: Dietary supplement intervention for 12-weeks</description>
        </group>
        <group group_id="P2">
          <title>9g of Placebo (Whey Protein)</title>
          <description>Twice a day for 12 consecutive weeks.&#xD;
Placebo (whey protein): Dietary supplement intervention for 12-weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>screening failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>9g of EAA Mixture Supplement</title>
          <description>Twice a day for 12 consecutive weeks.&#xD;
EAA mixture: Dietary supplement intervention for 12-weeks</description>
        </group>
        <group group_id="B2">
          <title>9g of Placebo (Whey Protein)</title>
          <description>Twice a day for 12 consecutive weeks.&#xD;
Placebo (whey protein): Dietary supplement intervention for 12-weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age &gt;=60 years.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White, non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Functional Test</title>
        <description>Measuring 6 minutes walking before and after the intervention. ***The results below are the actual increases of walking distance (mean and SD) changes from baseline to end of 12-week intervention.</description>
        <time_frame>Change from baseline to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>9g of EAA Mixture Supplement</title>
            <description>Twice a day for 12 consecutive weeks.&#xD;
EAA mixture: Dietary supplement intervention for 12-weeks</description>
          </group>
          <group group_id="O2">
            <title>9g of Placebo (Whey Protein)</title>
            <description>Twice a day for 12 consecutive weeks.&#xD;
Placebo (whey protein): Dietary supplement intervention for 12-weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Test</title>
          <description>Measuring 6 minutes walking before and after the intervention. ***The results below are the actual increases of walking distance (mean and SD) changes from baseline to end of 12-week intervention.</description>
          <units>feet</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.91" spread="94.727"/>
                    <measurement group_id="O2" value="57.25" spread="150.527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Subjects were followed for adverse events for the duration of their participation (approx. 4 months).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>9g of EAA Mixture Supplement</title>
          <description>Twice a day for 12 consecutive weeks.&#xD;
EAA mixture: Dietary supplement intervention for 12-weeks</description>
        </group>
        <group group_id="E2">
          <title>9g of Placebo (Whey Protein)</title>
          <description>Twice a day for 12 consecutive weeks.&#xD;
Placebo (whey protein): Dietary supplement intervention for 12-weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostate pain during urination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory issue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Scott Schutzler, R.N.</name_or_title>
      <organization>University of Arkansas for Medical Sciences</organization>
      <phone>501-526-5734</phone>
      <email>seschutzler@uams.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

